VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+3.91%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$245M
AUM Growth
+$31M
(+15%)
Cap. Flow
+$30.8M
Cap. Flow
% of AUM
12.58%
Top 10 Holdings %
Top 10 Hldgs %
7.31%
Holding
511
New
57
Increased
251
Reduced
151
Closed
49
Top Buys
| 1 |
SPDR Bloomberg High Yield Bond ETF
JNK
|
$1.88M |
| 2 |
DocuSign
DOCU
|
$1.49M |
| 3 |
United Airlines
UAL
|
$1.47M |
| 4 |
Fortinet
FTNT
|
$1.35M |
| 5 |
Spotify
SPOT
|
$1.34M |
Top Sells
| 1 |
Applovin
APP
|
$1.45M |
| 2 |
Expedia Group
EXPE
|
$1.04M |
| 3 |
KKR & Co
KKR
|
$976K |
| 4 |
CME Group
CME
|
$974K |
| 5 |
Corpay
CPAY
|
$948K |
Sector Composition
| 1 | Financials | 29.48% |
| 2 | Technology | 14.86% |
| 3 | Healthcare | 14.81% |
| 4 | Industrials | 11.61% |
| 5 | Consumer Discretionary | 6.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Edgewise Therapeutics
EWTX
$1.64B
| $67.4K | 0.03% |
2,526
-2,619
| -51% | -$69.9K |
|
|
MREO
402
Mereo BioPharma
MREO
$281M
| $66.7K | 0.03% |
+19,060
| New | +$66.7K |
|
403
EyePoint Pharmaceuticals
EYPT
$966M
| $66.7K | 0.03% |
+8,953
| New | +$66.7K |
|
|
LENZ
404
LENZ Therapeutics
LENZ
$1.2B
| $66.7K | 0.03% |
+2,309
| New | +$66.7K |
|
405
Vera Therapeutics
VERA
$1.54B
| $66.6K | 0.03% |
1,576
-889
| -36% | -$37.6K |
|
406
Cytokinetics
CYTK
$6.34B
| $66.6K | 0.03% |
1,415
-332
| -19% | -$15.6K |
|
407
Cogent Biosciences
COGT
$1.82B
| $66.5K | 0.03% |
8,524
-1,742
| -17% | -$13.6K |
|
|
RAPP
408
Rapport Therapeutics
RAPP
$524M
| $66.3K | 0.03% |
+3,740
| New | +$66.3K |
|
409
Vaxcyte
PCVX
$4.29B
| $66.2K | 0.03% |
809
-435
| -35% | -$35.6K |
|
410
Biohaven
BHVN
$1.68B
| $66.1K | 0.03% |
1,770
-990
| -36% | -$37K |
|
411
Xencor
XNCR
$610M
| $66K | 0.03% |
2,871
-1,452
| -34% | -$33.4K |
|
412
Dianthus Therapeutics
DNTH
$853M
| $65.9K | 0.03% |
3,025
-397
| -12% | -$8.66K |
|
413
Dyne Therapeutics
DYN
$2.02B
| $65.4K | 0.03% |
2,776
+40
| +1% | +$942 |
|
414
Crinetics Pharmaceuticals
CRNX
$3.35B
| $65.4K | 0.03% |
1,279
-683
| -35% | -$34.9K |
|
415
Perspective Therapeutics
CATX
$257M
| $65.4K | 0.03% |
20,487
+12,542
| +158% | +$40K |
|
416
Arcellx
ACLX
$4.03B
| $65.3K | 0.03% |
852
-799
| -48% | -$61.3K |
|
417
Arbutus Biopharma
ABUS
$805M
| $65.3K | 0.03% |
19,970
-9,192
| -32% | -$30.1K |
|
418
Savara
SVRA
$643M
| $65.2K | 0.03% |
21,222
-1,479
| -7% | -$4.54K |
|
419
Nurix Therapeutics
NRIX
$758M
| $65.1K | 0.03% |
3,458
-2,054
| -37% | -$38.7K |
|
420
Tyra Biosciences
TYRA
$674M
| $65.1K | 0.03% |
4,686
+44
| +0.9% | +$612 |
|
|
THRD
421
DELISTED
Third Harmonic Bio
THRD
| $65K | 0.03% |
+6,320
| New | +$65K |
|
422
Astria Therapeutics
ATXS
$424M
| $64.8K | 0.03% |
+7,247
| New | +$64.8K |
|
|
VERV
423
DELISTED
Verve Therapeutics
VERV
| $64.4K | 0.03% |
11,411
-5,044
| -31% | -$28.4K |
|
424
Nuvalent
NUVL
$5.83B
| $64.1K | 0.03% |
819
-346
| -30% | -$27.1K |
|
425
Tourmaline Bio
TRML
$687M
| $64K | 0.03% |
+3,157
| New | +$64K |
|